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Novel Aspects on Motor Neuron 




At present, with the advanced affordable genetic testing, the rate of discover-
ing amyotrophic lateral sclerosis (ALS)-related genes rapidly increases. These 
genetic findings provide new insights into therapies that target genetic subset of 
ALS. However, the research on the genetic and environmental causes of ALS is still in 
the early stage. In this chapter, we review the current understanding of ALS-related 
genes and summarize the worldwide ALS distribution feature by the frequency of 
occurrence in different regions. We summarize the advances in genetic testing and 
counseling for ALS. Based on the increase in genetic testing, we believe that the ALS 
patients and families would be benefited from our studies in the near future.
Keywords: ALS, genetic frequency features, GWAS, genetic testing, genetic counseling, 
genetic therapy
1. Introduction
Amyotrophic lateral sclerosis (ALS) is an adult onset and generally fatal 
neurodegenerative disease characterized by progressive weakness and atrophy of 
voluntary skeletal muscles due to dysfunction and death of upper and lower motor 
neurons. Onset typically occurs between 60 and 69 years of age, with wide-range 
severity. About 90% of cases are sporadic amyotrophic lateral sclerosis (SALS), 
while familial amyotrophic lateral sclerosis (FALS) accounts for the remaining 10% 
cases [1]. The pathogenesis of ALS remains obscure, but genetic mutations have 
been accounted for several impaired cellular and molecular mechanisms and, thus, 
provide clues for potential therapeutic strategies.
The superoxide dismutase 1 (SOD1), identified in 1993, was the first gene 
discovered to be associated with ALS. Subsequently, several gene mutations that 
have been identified to cause ALS. Till 2018, more than 180 genes have been identi-
fied as causative genes or related genes of ALS. Many of these genes are related to 
metabolism, trafficking of RNA, and chromatin, including C9orf 72, TDP43, FUS, 
TAF15, ELP3, ANG, hnRNPA1, and hnRNPA2B1 [2]. Some genes are involved in 
conformational instability and aggregation of proteins, such as SOD1, VCP, OPTN, 
and UBQLN2; others are related to axonal and cytoskeletal biology, such as PFN1, 
DCTN1, TUBA4A, and EPHA4 [2].
In most cases, FALS is inherited in the dominant pattern and the penetrance is 
associated with age. It has been observed that the differences of age onset and disease 
progression within and between ALS families are significant. In addition, some ALS 
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is recessive inherited, such as OPTN, SPG11, FUS, and SOD1 (definite, Asp90Ala 
homozygous mutation), and UBQLN2 associated ALS is X-linked dominant inher-
ited. Besides causative genes, multiple genetic variants interact simultaneously to 
increase ALS susceptibility. Considering oligogenic manner of ALS described by 
some researchers, many ALS patients may not appear to be familial in a conventional 
Mendelian manner. Therefore, the oligogenic manner may underlie the apparently 
sporadic form of the disease [3].
Some ALS caused by specific genetic mutations exhibit unique clinical charac-
teristics. For example, ALS associated with SPG11 and ALS3 has clinical features 
of early onset and slow progression. SPG11 mutations were identified in autosomal 
recessive juvenile ALS [4], and the patients with ALS3 mutations have an early 
onset of approximately 45 years and the average disease duration about 5 years.
Recently, progress in gene discovery and technology has both complicated and 
empowered the process of genetic testing options, which may help neurological 
clinicians and ALS patients to understand the pathogenesis of ALS, and then 
provide genetic counseling for family members, allow accurate risk assessment, 
and open the door for genotype-specific treatments. As the genetic basis of the 
remainder of FALS, and potentially SALS, is unraveled, genetic testing and coun-
seling will become increasingly vital and should be incorporated into the routine 
management of ALS [4–6].
2. Recent advances in ALS gene map
2.1 SOD1
The superoxide dismutase 1 (SOD1), located in 21q22, was discovered in 1993. 
Up to date, more than 180 mutations have been described to be associated with ALS, 
while most of these mutations are missense mutations. Its mutation probability 
accounts for 20% of FALS cases and 1–2% of SALS cases [1, 2, 7, 8].
2.2 C9orf 72
The C9orf 72, located in 9p21.2, was discovered in 2011. The protein encoded by 
C9orf 72 is mainly related to autophagy, endosomal transport, and immune func-
tion. According to statistics, about 40–50% of FALS and 10% of SALS carried the 
C9orf 72 expanded alleles. The pathogenic alleles of C9orf 72 may have hundreds or 
even thousands of the GGGGCC hexanucleotide repeats. A large number of clinical 
investigations have shown that about 700–1600 GGGGCC hexanucleotide repeats 
are inserted into the intron located between the two untranslated optional exons 1a 
and 1b of the C9orf 72 gene [1–3, 9, 10].
2.3 FUS
The FUS RNA-binding protein (FUS) gene, discovered in 2009, was mapped in 
16p11.2.
Mutations in FUS are observed in 4% of FALS and 1% of SALS. At present, more 
than 79 mutations have been described, predominantly in the 3′ region encoding an 
arginine/glycine-rich region and a NLS domain (nuclear localization signal). FUS 
protein, essentially localized in the nucleus, regulates RNA processing, splicing, 
and mRNA trafficking. Mutant FUS localized to cytoplasmic stress granules (SGs) 
and interacted with the stress granule protein PABP in an RNA-dependent manner 
resulting in mislocalization of the wildtype protein to stress granules [7–9, 11].
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2.4 CCNF
CCNF, located in 16p13.3, encoding the cyclin F, was first reported in 2016. The 
mutation of CCNF accounts for approximately 4% of FALS and 2% of SALS [7].
CCNF protein is a kind of kithe cell cyclin, involved in the regular of cell cycle 
transitions by activating cyclin-dependent protein kinases. Furthermore, it is the 
substrate recognition component of the Skp1-cullin-F-box E3 ubiquitin ligase 
complex. The neurons of the over-expressed mutant CCNF showed an increase in 
protein-labeled proteins, including TDP43. It indicates that mutated-CCNF protein 
interfere the proteasome degradation pathway by using traversing protein abnor-
malities to mark all proteins or inhibiting transferring transprotein-labeled proteins 
to proteasome complexes. This finding suggests that the CCNF mutation may cause 
abnormal protein homeostasis, which may be exacerbated by TDP43 protein disease.
Therefore, enhancing protein removal or reducing ubiquitin may be a feasible 
treatment [1, 3].
2.5 TIA1
The TIA1 gene, located in 2p13.3, encodes an RNA-binding protein involved 
in splicing regulation and translational repression. The mutations in TIA1 were 
identified in 2.2% of FALS and 0.4% of SALS [7]. TIA1 protein is a key component 
of SGs, cytoplasmic foci sequester untranslated mRNAs upon different types of 
cellular stress, and the low complexity domain (LCD) region of TIA1 plays a central 
role in promoting SGs assembly. A heterozygous founder mutation (E384K) in 
the LCD was first reported in Swedish/Finnish patients as the cause of Welander 
distal myopathy (WDM). Recently, a mutation (p.P362L) in TIA1 affecting a highly 
conserved residue in the LCD was identified as one cause of ALS/ALS-FTD [12].
2.6 TBK1
The TANK-binding kinase 1 (TBK1) gene, located in 12q14.2, was discovered 
in 2015 [7]. The protein encoded by this gene is similar to the IκB kinase and can 
mediate NFκb activation in response to certain growth factors. The TBK1 mutations 
were found in approximately 1% of FALS and 1% of SALS. The clinical phenotypes 
associated with the TBK1 mutation are heterogeneous, with different ages at onset, 
different progressions, and irregular survival times.
Some patients also reported with extrapyramidal, ataxia, or psychosis. 
Neuropathological examination of central nervous system (CNS) tissues from 
patients with TBK1 mutations revealed that SQSTM1/p62- and TDP-43-positive 
inclusion bodies which can indicate abnormalities in TDP-43 protein aggregation 
and protein clearance pathways [1, 2, 4, 5].
2.7 TARDBP
The TARDBP (trans-activation element DNA-binding protein), located in 
1p36.22, was discovered in 2008 [5].
The TARDBP gene mutation was found in 5% of FALS cases and 1% in SALS 
cases. Till now, more than 50 different mutations have been identified [9]. Except 
for D169G, a majority of these mutations are located in the 3′ region encoding a 
glycine-rich domain in its product, TDP-43. ALS patients carrying TARDBP gene 
mutations normally exhibit a classical ALS phenotype and rare dementia, they also 
have earlier disease onset, with upper limb onset being more common and compat-
ible with a longer life. Most of TDP-43 is expressed in nucleus, involved in RNA 
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metabolism in many ways—transcriptional regulation, splicing, mRNA stabiliza-
tion (including its own transcripts), and microRNA processing. TDP43 also regu-
lates axonal transport and neuronal plasticity. In ALS, TDP-43 is often observed in 
cytoplasm. The pathogenesis of TDP-43 mainly includes cytoplasm construction of 
high phosphorylation TDP-43 and clearance of nuclear TDP-43 [1, 2, 7, 8].
2.8 Pathogenesis of ALS-related genes
The cellular processes, including RNA processing, protein degradation path-
ways, ubiquitin-proteasome system (UPS), autophagy, and so on, are all reported 
related to ALS pathogenesis [1–3, 7–22]. Sorted by the various processes, we sum-
marize the causative genes and genes might increase susceptibility of ALS which 
impact physiological activities mentioned above (Figure 1).
Figure 2. 
The worldwide frequency of ALS-related genes. The x-axis is the time when genes discovered. The y-axis is 
the logarithms of the mutation frequency of genes in ALS. The mutation frequency of C9orf 72, CHCHD10, 
CCNF, KIF5A, and ANXA11 are only within FALS. Where gene frequency was not available (ALS2, SETX, 
SIGMAR1, and PDIA1), one “circle size” equivalent to 1% is given for illustrative purposes.
Figure 1. 
Dysfunction cellular processes and related genes contributed to the pathogenesis of ALS.
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2.9 Advances on gene discovery and frequency
We describe the worldwide ALS distribution feature by frequency of occurrence 
in different regions (Figure 2) [1–3, 7–9, 11, 14, 23, 24]. We summarize ALS muta-
tion genes frequency according to the researches in Mainland China (Figure 3).
3. GWAS on ALS
Recently, the studies on ALS have shown the development trend of the blowout 
with the technology improving, however, no longer limited by technical condition, 
the number of newly discovered ALS-related gene did not meet expectation. It 
indicates a shift in the genetic pathway that multiple genetic variants and environ-
mental factors may interact simultaneously to increase ALS susceptibility. On the 
basis of the fact that sporadic form apparently accounts for high rate of ALS and 
the hypothesis that ALS may not appear to be familial in a conventional Mendelian 
manner, a new research method, genome-wide association study (GWAS), is 
applied to the research of ALS.
Since GWAS was applied to complex diseases, remarkable achievements have 
been made in certain fields. It is also hoped that in this way, we will be able to find 
the risk factors of ALS [25–27].
3.1 SNPs and GWAS
The International HapMap Project, which began in 2002, mapped the single-
nucleotide polymorphisms (SNPs) haplotypes of the human genome from four major 
populations in the world and promoted the development of GWAS. At the same time, 
the rapid development of high-density and high-throughput genotyping technology, 
which can detect hundreds of thousands of SNPs in a single reaction, makes it pos-
sible to systematically screen mutations associated with complex diseases throughout 
the genome. Unlike previous candidate gene studies, GWAS does not need to build 
any assumptions based on disease pathophysiology prior to the study and can rela-
tively be an unbiased screen for almost all common mutations in the genome. At pres-
ent, some risk factors of complex diseases, such as age-related macular degeneration, 
diabetes mellitus, breast cancer, and so on, have been initially identified by GWAS.
Figure 3. 
ALS mutation genes frequency among FALS and SALS in Mainland China. The y-axis means the percentage 
of different mutation genes.
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3.2 ALS GWAS boot
Schymiek et al. firstly reported GWAS in SALS in February 2007 [28]. A total 
of 276 patients and 271 controls with white American ancestry were recruited in 
this research. They used a chip to detect 555,352 SNPs and found 34 of the most 
relevant SNPs by association analysis. For negative results, they elucidated that 
SALS might contain a group of diseases with similar clinical manifestations like 
FALS, each of which is determined by different mutation sites, and that different 
diseases and mutation sites may interfere with GWAS’s shooting out of susceptible 
genes. Among the 34 SNPs, there was an overexpression of genes associated with 
cytoskeletal actin regulation. For example, the KIAAl721 gene of rs11099864 and 
the FMN2 gene of rs1037666 had a homologous region that played an important 
role in the regulation of cytoskeletal actin. The most closely related rs4363506 of 
34 SNPs was located in the DOCKl gene, which plays an important role in nerve 
growth. Although no disease-susceptible gene was found, the study identified 
possible SNPs and published all the results, which facilitated subsequent large-
scale SALS GWAS studies.
Recently, a series of ALS GWAS studies have been published and found several 
potential risk genes [29–32]. However, the results of these studies are different with 
the same ideas and methods. The biological process of some candidate genes is 
unclear, and the evidence needs to be supplemented.
4. Genetic testing
Gene testing helps ALS patients and families enhance their understanding 
on the condition and information requested in genotype-specific treatments. 
Although ALS patients desire access to genetic testing, genetic advances have been 
slow to reach the clinical care of the ALS patient. In recent years, the landscape of 
genetic testing and genetic counseling for ALS has been rapidly transformed with 
the identification of novel genes and the advent of next-generation sequencing 
technology.
4.1 Genetic testing options
As with all clinical testing, genetic risk assessment, including family history and 
pedigree analysis, and pretest counseling, helping patients anticipate the possible 
impact of genetic testing on themselves and their family members, are necessary for 
patients before genetic testing.
Currently available genetic testing options for ALS include Sanger sequenc-
ing for traditional simple mutations, assays for the C9orf 72 repeat expansion, 
next-generation sequencing panels, whole-exome sequencing, and whole-genome 
sequencing.
4.2 Post-test counseling
Regarding the positive result, specific mutation, genotype-phenotype cor-
relations, family history, and inheritance pattern should be thoroughly analyzed. 
Meanwhile, implications and risks for family members, including offspring and 
siblings, and theories about why the disease occurs also should be reviewed and 
addressed. For the reported definite pathogenic mutations, clinicians should 
provide information and hope about the potential genetic therapies in the future.
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4.3 Presymptomatic testing
To increase certainty, make health or lifestyle choices, and make decisions about 
family planning, the presymptomatic testing could be conducted. According to the 
guidelines for presymptomatic genetic testing in other neurodegenerative diseases 
such as Huntington disease and Alzheimer disease, ALS should be tailored as fol-
lowing: pretest genetic counseling, baseline neurologic and cognitive assessment, 
psychological evaluation, in-person disclosure, presence of support person, and 
posttest genetic counseling. Most of important, presymptomatic testing should be 
offered to adult first-degree relatives of ALS patients with established mutations 
after written informed consent obtained [4].
5. Gene therapy
With the exception of riluzole, an anti-glutamatergic agent which was shown to 
prolong survival for 2–3 months by blocking the presynaptic release of glutamate, 
and edaravone, an antioxidant which was shown to decrease the rate of patient 
immobility, no effective treatment is currently available for ALS that can stop or 
reverse the disease progression.
Gene therapy is a promising therapeutic approach for ALS since it can be used to 
deliver “gene drugs,” encoding for blocking the novel gene expression, antiapoptotic 
proteins, and for neurotrophic factors, to the motor neurons crossing the blood-
brain barrier specifically to prevent further motor neuron degeneration and to 
preserve the function of remaining motor neurons.
Here, we are to illustrate some examples of each therapeutic strategy for describ-
ing the present status and advance of gene therapy treatment.
5.1 SOD1
The neurotoxicity of mutant SOD1 is related to the dose of the toxic protein 
through multiple pathological mechanisms. A potential therapeutic approach to SOD1-
related ALS is to block the expression of the toxic SOD1 that could cause motor neuron 
degeneration [33]. This therapy option which is more worthy of attention is that it pos-
sibly avoids and decreases potential influence in downstream pathological cascades. 
Recently, the studies mostly focus on antisense oligonucleotides and RNA interference 
which are both to block gene expression through enhancing the degradation of RNA.
5.1.1 Antisense oligonucleotides in models and human
In animal models of SOD1-associated ALS, antisense oligonucleotide treatment 
significantly delayed disease onset, improved neuromuscular function, and pro-
longed survival.
The first clinical trial of antisense oligonucleotide treatment in human beings 
had favorable safety outcomes, and now the clinical trial to assess the safety, toler-
ability, and pharmacokinetics of a second generation SOD1 antisense oligonucle-
otide is in progress (Clinical Trials.Gov, NCT02623699) [34].
5.1.2 Short hairpin RNA (shRNA) treatment in mutant SOD1 ALS models
According to literature, in SOD1G93A mice, reduction of human SOD1 expres-
sion can significantly slow ALS progression and extend survival by using a single 
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peripheral injection of an adeno-associated virus serotype 9 (AAV9) encoding 
shRNA [35].
While, in a recent study reported, SOD1 expression in the motor cortex of P70 
SOD1G93A models was selectively silenced by delivery of AAV9-SOD1-shRNA. As 
a result, not only the ALS progression was slowed and the survival was extended 
significantly, but also the survival of spinal motor neurons was significantly 
enhanced [36].
5.1.3  miRNA treatment in mutant SOD1 ALS models and healthy nonhuman primates
In a study, scientists reported a new method that systemically delivered drug 
based on an artificial microRNA. In the SOD1G93A mice, this drug delayed ALS 
onset, prolonged the survival, and significantly preserved muscle strength and 
motor and respiratory functions. Notably, the research of this drug has been con-
ducted in nonhuman primates, and the result showed that SOD1 expression in lower 
motor neurons was safely blocked [37].
5.2 C9orf 72
Similar therapeutic approach targeting C9orf72 for ALS is also in development. 
The toxicity of mutated C9orf72 is imparted by the formation of nucleolar RNA 
foci that sequester important RNA-binding proteins and by the generation of toxic 
dipeptide repeat (DPR) proteins.
The C9orf72 hexanucleotide repeat expansion (HRE) of GGGGCC DNA and 
RNA enables the formation of complex structures including G-quadruplexes. 
Because the Guanosine-rich DNA and RNA sequences are prone to formation of 
G-quadruplexes, a stable four-stranded structure present within ribosomal DNA 
sequences, transcription start sites, the promoter and untranslated regions of 
mRNA, human telomeric DNA sequences. It may play an important role in vari-
ous cellular processes such as telomere maintenance, ribosome biogenesis, gene 
replication, transcription, and translation. Therefore, both C9orf72 HRE DNA and 
RNA may contribute to the pathogenesis of ALS/FTD disease through a mecha-
nism associated with their structure polymorphism. Presently, based on the above 
mechanism, two strategies including antisense-mediated interventions and small-
molecule-based approach have been developed to interfere with neurodegenerative 
diseases associated with G-quadruplexes [38].
5.2.1 Antisense oligonucleotides in mutant C9orf72 ALS models
A recent study reported that the RNA foci and DPR proteins were reduced 
significantly in mutant C9orf72 ALS mice by a single-dose injection of antisense 
oligonucleotides to reduce C9orf72 RNA repeats, and after 6 months of treatment, 
the motor function was also preserved [39].
5.2.2  Small-molecule ligands targeting the G-quadruplex structure in mutant 
C9orf72 cells
The small-molecule ligands, such as porphyrin, acridine, pentacridium, 
telomestatin, naphthalene diamide, and bisquinolium, directly target and bind 
to the G-quadruplex structure and selectively modulated the function of the 
G-quadruplex. For example, TMPyP4, a cationic porphyrin, can bind and disrupt 
the secondary structures of C9orf72 HRE and even damage its interactions with 
hnRNPA1 and ASF/SF2 proteins [40].
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Similarly, some studies also showed that three small-molecule ligands can bind 
G-quadruplex and decreased RNA foci and RNA translation in both cultured cells 
and patient-derived neurons [41].
5.3 Others
TBK1 is a key regulatory molecule upstream of OPTN, SQSTM1/p62, and 
IRF3 in the autophagy and neuroinflammatory pathways that are implicated in 
ALS. Manipulation of TBK1 might potentially compensate for defects caused by 
other ALS-associated proteins in these pathways—for example, VCP and UBQLN2. 
NEK1 and C21orf2 are known to interact at the protein level and, in addition to 
TUBA4A, PFN1, NEFH, and PRPH, they represent the building blocks of the cel-
lular scaffold. Administration of small molecules that enhance cytoskeletal integrity 
could represent a viable therapy for stopping progression or reversing the disease 
course in patients with these mutations [4–6].
6. Conclusion
Nearly a decade ago, the only way to test ALS-related gene was SOD1 sequenc-
ing, whereas clinicians now have a wide availability of testing options already. 
Whole-exome sequencing is current standard in most related searches. However, 
the factors such as high rate of incomplete penetrance in ALS, few large pedigrees, 
and short survival of patients lead to the discovery of ALS-related genes worse than 
expected and the identification of susceptible mutations limited.
Although many known ALS-related genes’ structural characteristics and roles 
have been discovered, which have highlighted critical processes, pathways, and 
intracellular localizations of dysregulation, there are still many reported variants 
with uncertain significance. Further functional studies are needed to clarify the 
pathogenesis of these genes. Till now, more people believe that ALS is the result of 
interaction between multiple genes that each increases the susceptibility of the dis-
ease, but does not initiate the pathogenesis alone. So, we need to do more research 
on oligogenic ALS cases. Most importantly, with the improvement of understanding 
of ALS genetics, we will have more opportunities to develop meaningful therapies.
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